[UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects]. 1987

H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada

The concentrations of FT, 5-FU and uracil in lung cancer tissue, healthy lung tissue and serum were measured in 10 patients with primary lung cancer to whom UFT (600 mg) had been administered for one week. No remarkable difference was found in the concentration of FT between both tissues. The concentration of 5-FU in lung cancer tissue was 0.099 +/- 0.051 microgram/g and significantly higher than the level of 0.009 +/- 0.003 microgram/ml in serum (p less than 0.001) and 0.039 +/- 0.021 microgram/g in normal lung tissue (p less than 0.01). The ratio of 5-FU concentration in cancerous tissue to that in the serum was 11.0, while the ratio of the level in cancerous tissue to that in normal lung tissue was 2.5. The concentration of uracil was much higher in cancerous tissue than in normal lung tissue and serum. Maintenance therapy with UFT proved possible for a long period in 11 primary lung cancer patients with negligible digestive side effects.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
March 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
July 1991, Hinyokika kiyo. Acta urologica Japonica,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
October 1986, Hinyokika kiyo. Acta urologica Japonica,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
August 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
February 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
November 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
H Kato, and S Inoue, and K Takahashi, and A Yamanaka, and Y Okada
October 2000, Oncology (Williston Park, N.Y.),
Copied contents to your clipboard!